SCNI Scinai Immunotherapeutics Quick Ratio

The market dynamics of Scinai Immunotherapeutics (SCNI) rely on its integration into a contract biomanufacturing network, where GMP certification creates a defensive barrier. The current metric stands at 1.49. The business focuses on developing antibodies for the therapy of skin inflammation, targeting individuals with psoriasis. The biotech startup's financial stability depends on grants and nanobody trial results, as stable profits are currently absent.

For Scinai Immunotherapeutics (SCNI), which focuses on the agile development of nanobodies, capital mobility is critical for rapid R&D. This metric assesses the company's ability to settle short-term liabilities using only cash and accounts receivable, completely excluding illiquid inventories. By analyzing the acid-test ratio, an investor gains a real-time assessment of the business's margin of safety without accounting for warehouse stocks. The stability of this metric confirms financial resilience while scaling the technological platform.